A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors

Journal of Immunotherapy

Volumn 34, Issue 7, 2011, Pages 556-567

  Weber, Jeffrey S ^a   Vogelzang, Nicholas J ^b   Ernstoff, Marc S ^c   Goodman, Oscar B ^b   Cranmer, Lee D ^d   Marshall, John L ^e   Miles, Sabrina ^f   Rosario, Dar ^f   Diamond, David C ^f   Qiu, Zhiyong ^f   Obrocea, Mihail ^f   Bot, Adrian ^f  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NEVADA CANCER INSTITUTE   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f MannKind Corporation   (United States)

Author keywords

Active immunotherapy; intralymph node vaccination; PRAME; PSMA; solid tumor

Indexed keywords

CANCER VACCINE; HLA A ANTIGEN; MKC1106 PP; MKC1106 PP VACCINE; PLASMID DNA; PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TETRAMER; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BASAL CELL CARCINOMA; BOLUS INJECTION; CANCER IMMUNIZATION; CELL DIFFERENTIATION; CHILL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; GENE TARGETING; GENETIC CODE; GENETIC STABILITY; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INJECTION SITE PAIN; INJECTION SITE REACTION; KIDNEY CARCINOMA; MALE; MELANOMA; MESOTHELIOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CARCINOMA; RASH; RECOMBINANT PLASMID; SOLID TUMOR; T LYMPHOCYTE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CANCER VACCINES; CYTOKINES; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 80051550377     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182280db1     Document Type: Article

References (42)

1. Jones D. Rethinking therapeutic cancer vaccines. Nat Rev Drug Discov. 2009;8:S685-S686.
2. Morse MA, Whelan M. A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther. 2010;12:11-13.
3. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med. 2004;350:1461-1463. (Pubitemid 38420003)
4. Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther. 2008;8:951-968. (Pubitemid 352007006)
5. Old LJ. Cancer vaccines: an overview. Cancer Immun. 2008;8:S1.
6. Epping MT, Wang L, Edel MJ, et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122:835-847. (Pubitemid 41345202)
7. Paydas S. Is everything known in all faces of iceberg in PRAME? Leuk Res. 2008;32:1356-1357.
8. Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostatespecific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol. 2005;288:C975-C981. (Pubitemid 40559373)
9. Slovin SF. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets. 2005;9:561-570. (Pubitemid 40883153)
10. Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26: 5310-5324. (Pubitemid 44036201)
11. Oehler VG, Guthrie KA, Cummings CL, et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood. 2009;114:3299-3308.
12. Griffioen M, Kessler JH, Borghi M, et al. Detection and functional analysis of CD8+T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res. 2006;12:3130-3136. (Pubitemid 43837361)
13. Murphy GP, Elgamal AA, Su SL, et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998;83:2259-2269. (Pubitemid 28533495)
14. Rajasekaran SA, Christiansen JJ, Schmid I, et al. Prostatespecific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther. 2008;7:2142-2151.
15. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res. 2002;62:5807-5812. (Pubitemid 35204739)
16. Manyak MJ. Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther. 2008;8:175-181. (Pubitemid 351385907)
17. Maloy KJ, Erdmann I, Basch V, et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA. 2001;98:3299-3303. (Pubitemid 32220840)
18. Johansen P, Hä ffner AC, Koch F, et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol. 2005;35:568-574. (Pubitemid 40331333)
19. Smith KA, Tam VL, Wong RM, et al. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine. 2009;27:2603-2615.
20. Smith KA, Qiu Z, Wong R, et al. Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination. Can Gene Ther. 2011;18:63-76.
21. Tagawa ST, Lee P, Snively J, et al. Phase 1 study of intranodal delivery of a plasmid DNA vaccine for subjects with stage IV melanoma. Cancer. 2003;1:144-154. (Pubitemid 36741137)
22. Weber J, Boswell W, Smith J, et al. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother. 2008;31: 215-223.
23. Micheletti F, Bazzaro M, Canella A, et al. The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses. Immunology. 1999;96:411-415. (Pubitemid 29118329)
24. Elsä sser-Beile U, Bü hler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10:118-125.
25. Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007;2:182-190. (Pubitemid 47554839)
26. Todorova K, Ignatova I, Tchakarov S. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun. 2005;5:1.
27. Low L, Mander A, McCann K. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther. 2009;20:1269-1278.
28. Matsushita M, Yamazaki R, Ikeda H, et al. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies. Leuk Lymphoma. 2003;44:439-444. (Pubitemid 36113886)
29. Tsuji T, Altorki NK, Ritter G, et al. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J Immunol. 2009;183:4800-4808.
30. Ribas A, Weber JS, Chmielowski B, et al. Intra-Lymph node prime-boost vaccination against Melan A and Tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin Cancer Res. 2011;17:2987-2996.
31. Nielsen MB, Marincola FM. Melanoma vaccines: the paradox of T cell activation without clinical response. Cancer Chemother Pharmacol. 2000;46(Suppl):S62-S66.
32. Lee KH, Panelli MC, Kim CJ, et al. Functional dissociation between local and systemic immune response during antimelanoma peptide vaccination. J Immunol. 1998;161: 4183-4194. (Pubitemid 28469000)
33. Kochenderfer JN, Gress RE. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp Biol Med (Maywood). 2007;232:1130-1141. (Pubitemid 47503054)
34. Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol. 2001;166:4254-4259.
35. Lesimple T, Neidhard EM, Vignard V, et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res. 2006;12:7380-7388. (Pubitemid 46095412)
36. Verdijk P, de Vries Figdor, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res. 2009;15:2531-2540.
37. Gimotty PA, Guerry D, Flaherty K. Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients. J Clin Oncol. 2008;26:517-518. (Pubitemid 351264341)
38. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527-534. (Pubitemid 351264344)
39. Lin Y, Gallardo HF, Ku GY, et al. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy. 2009;11:1-11.
40. Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010;20: 241-246.
41. Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer: when TKIs are not enough. Nat Rev Clin Oncol. 2009;6:478-487.
42. Heine A, Holderried TA, Brossart P. Immunotherapy in renal cell carcinoma. Immunotherapy. 2009;1:97-107.